Efficacy of New Hepatic Arterial Infusion Chemotherapy with Lipiodol, a New-FP Therapy for Unresectable Advanced Intrahepatic Cholangiocarcinoma (iCCA)

Objective Intrahepatic cholangiocarcinoma (iCCA) is an aggressive malignancy with limited treatment options in the unresectable setting. Although gemcitabine plus cisplatin-based chemotherapy combined with immune checkpoint inhibitors is the current first-line standard of care, clinical outcomes remain limited. Hepatic arterial infusion chemotherapy (HAIC) may provide locoregional tumor control in selected patients. We evaluated the feasibility and local antitumor activity of HAIC with Lipiodol ("New FP," NFP) in unresectable iCCA, with gemcitabine plus cisplatin (GC) presented for reference.